Exploring sequence requirements for C3/C4 carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase

Protein Science

Volumn 20, Issue 6, 2011, Pages 941-958

  Drawz, Sarah M ^a   Taracila, Magdalena ^a   Caselli, Emilia ^b   Prati, Fabio ^b   Bonomo, Robert A ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

lactamase inhibitor resistance; AmpC cephalosporinases; Pseudomonas aeruginosa

Indexed keywords

ALANINE; AMINO ACID; AMPICILLIN; AZTREONAM; BETA LACTAM; BETA LACTAMASE AMPC; BORONIC ACID DERIVATIVE; CARBON; CARBOXYLIC ACID; CEFALORIDINE; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CLAVULANIC ACID; IMIPENEM; MEROPENEM; NITROCEFIN; PENICILLIN G; PIPERACILLIN; TAZOBACTAM; TETRAHYDROFURAN; THIAZOLIDINE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME KINETICS; HYPOTHESIS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; BINDING SITES; BORONIC ACIDS; CEPHALOSPORINASE; CEPHALOSPORINS; CEPHALOTHIN; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; SEQUENCE ALIGNMENT; SUBSTRATE SPECIFICITY;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 79956206767     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.612     Document Type: Article

References (72)

1. Page MG, Heim J (2009) Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol 9:558-565.
2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK (2008) NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29: 996-1011.
3. Gaynes R, Edwards JR (2005) Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 41:848-854. (Pubitemid 41266753)
4. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, Gatell JM, Soriano E, Jimenez de Anta MT (1996) Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156:2121-2126. (Pubitemid 26346971)
5. Rahal JJ (2006) Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43(Suppl 2):S95-S99.
6. Goossens H (2003) Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 9:980-983.
7. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW (2010) Prevalence, mechanism and susceptibility of multidrug resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 54: 1160-1164.
8. Rice LB (2009) The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 12:476-481.
9. Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634-640.
10. Walsh TR (2010) Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 36(Suppl 3): S8-S14.
11. Hanson ND, Sanders CC (1999) Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr Pharm Des 5:881-894.
12. Juan C, Gutierrez O, Oliver A, Ayestaran JI, Borrell N, Perez JL (2005) Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin Microbiol Infect 11:887-892. (Pubitemid 41535925)
13. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y (1993) Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 37:851-858. (Pubitemid 23096890)
14. Monnaie D, Frere JM (1993) Interaction of clavulanate with class C β-lactamases. FEBS Lett 334:269-271.
15. Kazmierczak A, Cordin X, Duez JM, Siebor E, Pechinot A, Sirot J (1990) Differences between clavulanic acid and sulbactam in induction and inhibition of cephalosporinases in enterobacteria. J Int Med Res 18(Suppl 4):67D-77D.
16. Blizzard TA, Chen H, Kim S, Wu J, Young K, Park YW, Ogawa A, Raghoobar S, Painter RE, Hairston N, Lee SH, Misura A, Felcetto T, Fitzgerald P, Sharma N, Lu J, Ha S, Hickey E, Hermes J, Hammond ML (2010) Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem. Bioorg Med Chem Lett 20:918-921.
17. Rodriguez-Martinez JM, Poirel L, Nordmann P (2009) Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53: 1766-1771.
18. Jacob-Dubuisson F, Lamotte-Brasseur J, Dideberg O, Joris B, Frere JM (1991) Arginine 220 is a critical residue for the catalytic mechanism of the Streptomyces albus G β-lactamase. Protein Eng 4:811-819.
19. Knox JR, Moews PC (1991) β-lactamase of Bacillus licheniformis 749/C. Refinement at 2 A resolution and analysis of hydration. J Mol Biol 220:435-455.
20. Imtiaz U, Billings EM, Knox JR, Manavathu EK, Lerner SA, Mobashery S (1993) Inactivation of class A β-lactamases by clavulanic acid: the role of Arginine 244 in a proposed noncerted sequence of events. J Am Chem Soc 115:4435-4442. (Pubitemid 23197971)
21. Zafaralla G, Manavathu EK, Lerner SA, Mobashery S (1992) Elucidation of the role of Arginine-244 in the turnover processes of class A β-lactamases. Biochemistry 31:3847-3852.
22. Thomson JM, Distler AM, Bonomo RA (2007) Overcoming resistance to β-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244. Biochemistry 46:11361-11368. (Pubitemid 47556763)
23. Moews PC, Knox JR, Dideberg O, Charlier P, Frere JM (1990) β-lactamase of Bacillus licheniformis 749/C at 2 A resolution. Proteins 7:156-171. (Pubitemid 20108783)
24. Marciano DC, Brown NG, Palzkill T (2009) Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM-1 β-lactamase. Protein Sci 18:2080-2089.
25. Perez-Llarena FJ, Cartelle M, Mallo S, Beceiro A, Perez A, Villanueva R, Romero A, Bonnet R, Bou G (2008) Structure-function studies of arginine at position 276 in CTX-M b-lactamases. J Antimicrob Chemother 61:792-797. (Pubitemid 351426061)
26. Beadle BM, Shoichet BK (2002) Structural basis for imipenem inhibition of class C β-lactamases. Antimicrob Agents Chemother 46:3978-3980. (Pubitemid 35403277)
27. Lobkovsky E, Billings EM, Moews PC, Rahil J, Pratt RF, Knox JR (1994) Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a β-lactamase transition-state analog. Biochemistry 33: 6762-6772. (Pubitemid 24190798)
28. Morandi F, Caselli E, Morandi S, Focia PJ, Blazquez J, Shoichet BK, Prati F (2003) Nanomolar inhibitors of AmpC β-lactamase. J Am Chem Soc 125:685-695.
29. Dubus A, Wilkin JM, Raquet X, Normark S, Frere JM (1994) Catalytic mechanism of active-site serine β-lactamases: role of the conserved hydroxy group of the Lys-Thr(Ser)-Gly triad. Biochem J 301(Pt 2):485-494.
30. Zhang Z, Yu Y, Musser JM, Palzkill T (2001) Amino acid sequence determinants of extended spectrum cephalosporin hydrolysis by the class C P99 β-lactamase. J Biol Chem 276:46568-46574.
31. Patera A, Blaszczak LC, Shoichet B (2000) Crystal structures of substrate and inhibitor complexes with AmpC β-lactamase: possible implications for substrate-assisted catalysis. J Am Chem Soc 122:10504-10512.
32. Beadle BM, Trehan I, Focia PJ, Shoichet BK (2002) Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC β-lactamase. Structure 10:413-424. (Pubitemid 34230628)
33. Powers RA, Shoichet BK (2002) Structure-based approach for binding site identification on AmpC β-lactamase. J Med Chem 45:3222-3234. (Pubitemid 34774273)
34. Tomatis PE, Fabiane SM, Simona F, Carloni P, Sutton BJ, Vila AJ (2008) Adaptive protein evolution grants organismal fitness by improving catalysis and flexibility. Proc Natl Acad Sci USA 105:20605-20610.
35. Todd AE, Orengo CA, Thornton JM (2002) Plasticity of enzyme active sites. Trends Biochem Sci 27:419-426. (Pubitemid 34874752)
36. Brown NG, Pennington JM, Huang W, Ayvaz T, Palzkill T (2010) Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β-lactamases. J Mol Biol 404:832-846.
37. Endimiani A, Doi Y, Bethel CR, Taracila M, Adams-Haduch JM, O'Keefe A, Hujer AM, Paterson DL, Skalweit MJ, Page MG, Drawz SM, Bonomo RA (2010) Enhancing resistance to cephalosporins in class C β-lactamases: impact of Gly214Glu in CMY-2. Biochemistry 9:1014-1023.
38. Galleni M, Amicosante G, Frere JM (1988) A survey of the kinetic parameters of class C β-lactamases. Cephalosporins and other β-lactam compounds. Biochem J 255:123-129.
39. Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR, Thomson JM, Anderson VE, Barlow M, Rice LB, Tenover FC, Bonomo RA (2005) Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 49:2941-2948.
40. Powers RA, Caselli E, Focia PJ, Prati F, Shoichet BK (2001) Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: implications for resistance mutations and inhibitor design. Biochemistry 40:9207-9214. (Pubitemid 32730042)
41. Bush K, Freudenberger JS, Sykes RB (1982) Interaction of azthreonam and related monobactams with β-lactamases from gram-negative bacteria. Antimicrob Agents Chemother 22:414-420. (Pubitemid 13241702)
42. Oefner C, D'Arcy A, Daly JJ, Gubernator K, Charnas RL, Heinze I, Hubschwerlen C, Winkler FK (1990) Refined crystal structure of β-lactamase from Citrobacter freundii indicates a mechanism for β-lactam hydrolysis. Nature 343:284-288.
43. Mourey L, Miyashita K, Swaren P, Bulychev A, Samama JP, Mobashery S (1998) Inhibition of the NMC-A β-lactamase by a penicillanic acid derivative and the structural bases for the increase in substrate profile of this antibiotic resistance enzyme. J Am Chem Soc 120:9382-9383. (Pubitemid 28452721)
44. Chen CC, Rahil J, Pratt RF, Herzberg O (1993) Structure of a phosphonate-inhibited β-lactamase. An analog of the tetrahedral transition state/intermediate of β-lactam hydrolysis. J Mol Biol 234:165-178. (Pubitemid 23337972)
45. Crompton IE, Cuthbert BK, Lowe G, Waley SG (1988) β-lactamase inhibitors. The inhibition of serine β-lactamases by specific boronic acids. Biochem J 251: 453-459.
46. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211-1233.
47. Drawz SM, Bonomo RA (2010) Three decades of β-lactamase inhibitors. Clin Microbiol Rev 23:160-201.
48. Lobkovsky E, Moews PC, Liu H, Zhao H, Frere JM, Knox JR (1993) Evolution of an enzyme activity: crystallographic structure at 2-A resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc Natl Acad Sci USA 90:11257-11261. (Pubitemid 23354408)
49. Morandi S, Morandi F, Caselli E, Shoichet BK, Prati F (2008) Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors. Bioorg Med Chem 16:1195-1205. (Pubitemid 351191778)
50. Michaux C, Massant J, Kerff F, Frere JM, Docquier JD, Vandenberghe I, Samyn B, Pierrard A, Feller G, Charlier P, Van Beeumen J, Wouters J (2008) Crystal structure of a cold-adapted class C β-lactamase. FEBS J 275:1687-1697. (Pubitemid 351463987)
51. Feller G, Gerday C (2003) Psychrophilic enzymes: hot topics in cold adaptation. Nat Rev Microbiol 1:200-208.
52. Wang X, Minasov G, Shoichet BK (2002) Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 320:85-95. (Pubitemid 34722236)
53. Kim JY, Jung HI, An YJ, Lee JH, Kim SJ, Jeong SH, Lee KJ, Suh PG, Lee HS, Lee SH, Cha SS (2006) Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol Microbiol 60:907-916.
54. Khersonsky O, Tawfik DS (2010) Enzyme promiscuity: a mechanistic and evolutionary perspective. Annu Rev Biochem 79:471-505.
55. Caselli E, Powers RA, Blasczcak LC, Wu CY, Prati F, Shoichet BK (2001) Energetic, structural, and antimicrobial analyses of β-lactam side chain recognition by β-lactamases. Chem Biol 8:17-31. (Pubitemid 32165809)
56. Davoli P, Fava R, Spaggiari A, Morandi S, Prati F (2005) Enantioselective total synthesis of (-)-microcarpalide. Tetrahedron 61:4427-4436.
57. Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201. (Pubitemid 43205406)
58. Kryshtafovych A, Fidelis K (2009) Protein structure prediction and model quality assessment. Drug Discov Today 14:386-393.
59. Diller DJ, Merz KM Jr (2001) High throughput docking for library design and library prioritization. Proteins 43:113-124.
60. Clinical and Laboratory Standard Institute (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard, CLSI document M7-A7, 7th ed., Wayne, PA.
61. Berks M, Redhead K, Abraham EP (1982) Isolation and properties of an inducible and a constitutive b-lactamase from Pseudomonas aeruginosa. J Gen Microbiol 128:155-159. (Pubitemid 12139350)
62. Flett F, Curtis NA, Richmond MH (1976) Mutant of Pseudomonas aeruginosa 18S that synthesizes type Id β-lactamase constitutively. J Bacteriol 127: 1585-1586.
63. Lodge JM, Minchin SD, Piddock LJ, Busby JW (1990) Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC β-lactamase. Biochem J 272: 627-631.
64. Knott-Hunziker V, Petursson S, Jayatilake GS, Waley SG, Jaurin B, Grundstrom T (1982) Active sites of β-lactamases. The chromosomal β-lactamases of Pseudomonas aeruginosa and Escherichia coli. Biochem J 201: 621-627.
65. Drawz SM, Babic M, Bethel CR, Taracila M, Distler AM, Ori C, Caselli E, Prati F, Bonomo RA (2010) Inhibition of the class C β-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry 49:329-340.
66. Hujer AM, Hujer KM, Helfand MS, Anderson VE, Bonomo RA (2002) Amino acid substitutions at Ambler position Gly238 in the SHV-1 β-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins. Antimicrob Agents Chemother 46: 3971-3977. (Pubitemid 35403276)
67. Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M, Anderson VE, Fritsche TR, Jones RN, Pagadala SR, van den Akker F, Buynak JD, Bonomo RA (2009) Strategic design of an effective β-lactamase inhibitor: LN-1-255, A 6-alkylidene-20-substituted penicillin sulfone. J Biol Chem 284:945-953.
68. Thomson JM, Distler AM, Prati F, Bonomo RA (2006) Probing active site chemistry in SHV β-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J Biol Chem 281: 26734-26744. (Pubitemid 44401882)
69. Chen Y, Shoichet B, Bonnet R (2005) Structure, function, and inhibition along the reaction coordinate of CTX-M β-lactamases. J Am Chem Soc 127:5423-5434. (Pubitemid 40569854)
70. Wang X, Minasov G, Blazquez J, Caselli E, Prati F, Shoichet BK (2003) Recognition and resistance in TEM β-lactamase. Biochemistry 42:8434-8444.
71. Copeland RA (2005)Evaluation of Enzyme Inhibitors in Drug Discovery; John Wiley & Sons, Inc.
72. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.